EQRx adds armor to its discount checkpoint inhibitor submission, nailing survival mark in key study
The rules say you can’t disrupt any market unless you are, in fact, a part of that market — and self-styled drug pricing disruptor EQRx is one step closer to doing just that.
A combination of EQRx and CStone’s PD-(L)1 drug sugemalimab and chemotherapy significantly prolonged patients’ lives over placebo in patients with newly diagnosed stage IV non-small cell lung cancer, according to updated data from the Phase III GEMSTONE-302 study unveiled Tuesday evening.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.